The gut may be involved in the development of multiple sclerosis

Summary: Increased levels of Smad7 in T-cells is linked to multiple sclerosis-like symptoms in mice. In the intestines, the T-cells were more frequently activated and migrated to the central nervous system, where they triggered inflammation. Similar activation was seen in human patients with multiple sclerosis. The findings provide further evidence that multiple sclerosis may start in the intestines and spread via the CNS.

Source: RUB

It is incompletely understood which factors in patients with multiple sclerosis (MS) act as a trigger for the immune system to attack the brain and spinal cord. A potential factor is described by a research team in the journal Proceedings of the National Academy of Sciences, PNAS. The medical researchers used an animal model to show that the protein Smad7 mobilizes immune cells in the intestines which, in turn, trigger inflammation in the central nervous system. Analyses of intestinal tissue samples taken from MS patients confirmed the results, which were published online on 4 December 2019.

The study was conducted at the Department of Neurology and the Centre of Neuroimmunology at St. Josef-Hospital, university hospital of Ruhr-Universität Bochum. The Bochum-based group with biologist Dr. Steffen Haupeltshofer and neurologists Professor Simon Faissner and Professor Ingo Kleiter, formerly at the Bochum university hospital, currently at Marianne-Strauß-Klinik in Berg, collaborated with other colleagues from Bochum, Bremen, Mainz, Düsseldorf, Jülich and Rome.

Protein Smad7 activates immune cells in the intestines

The research team initially analysed the signal protein Smad7 in intestinal immune cells in mice, or more precisely: in T-cells. The researchers compared genetically modified mice with a normal and those with a particularly high quantity of Smad7 in T-cells as well as mice without any Smad7 in T-cells. They monitored if the animals developed opticospinal encephalomyelitis – a disease that mimics MS in humans.

This shows a skeleton and a computer screen with a brain on it

In addition, an abnormal ratio of regulatory to pathogenic mechanisms was identified in intestinal mucosa samples in patients. The image is in the public domain.

The strongest clinical MS-like symptoms occurred in animals with an increased Smad7 level in T-cells. In their intestines, T-cells were more frequently activated, which then migrated into the central nervous system where they triggered inflammation. Moreover, the ratio of protective regulatory T-cells to pathogenic autoreactive T-cells had changed. In mice that didn’t have any Smad7 protein, no clinical signs of a MS-like disease occurred.

Results confirmed using tissue samples from patients

In the next step, the researchers analysed tissue samples taken from the intestines of 27 MS patients and compared them with samples taken from 27 healthy individuals. In the patients, they identified changes similar to those in the animal model: the signal protein Smad7 occurred more frequently in intestinal mucosa samples of MS patients than in those of healthy individuals; in addition, an abnormal ratio of regulatory to pathogenic mechanisms was identified in intestinal mucosa samples in patients.

“For other autoimmune diseases such as Crohn’s and other inflammatory bowel diseases, researchers are already aware that Smad7 offers a promising therapeutic target; our results suggest that the same is true for multiple sclerosis,” says Ingo Kleiter. “Researchers are increasingly exploring intestinal involvement in the development and progression of MS,” adds Simon Faissner.

About this neuroscience research article

Source:
RUB
Media Contacts:
Simon Faissner – RUB
Image Source:
The image is in the public domain.

Original Research: Closed access
“Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis”. Steffen Haupeltshofer, Teresa Leichsenring, Sarah Berg, Xiomara Pedreiturria, Stephanie C. Joachim, Iris Tischoff, Jan-Michel Otte, Tobias Bopp, Massimo C. Fantini, Charlotte Esser, Dieter Willbold, Ralf Gold, Simon Faissner, and Ingo Kleiter.
PNAS doi:10.1073/pnas.1905955116.

Abstract

Smad7 in intestinal CD4+ T cells determines autoimmunity in a spontaneous model of multiple sclerosis

Environmental triggers acting at the intestinal barrier are thought to contribute to the initiation of autoimmune disorders. The transforming growth factor beta inhibitor Smad7 determines the phenotype of CD4+ T cells. We hypothesized that Smad7 in intestinal CD4+ T cells controls initiation of opticospinal encephalomyelitis (OSE), a murine model of multiple sclerosis (MS), depending on the presence of gut microbiota. Smad7 was overexpressed or deleted in OSE CD4+ T cells to determine the effect on clinical progression, T cell differentiation, and T cell migration from the intestine to the central nervous system (CNS). Smad7 overexpression worsened the clinical course of OSE and increased CNS inflammation and demyelination. It favored expansion of intestinal CD4+ T cells toward an inflammatory phenotype and migration of intestinal CD4+ T cells to the CNS. Intestinal biopsies from MS patients revealed decreased transforming growth factor beta signaling with a shift toward inflammatory T cell subtypes. Smad7 in intestinal T cells might represent a valuable therapeutic target for MS to achieve immunologic tolerance in the intestine and suppress CNS inflammation.

Feel free to share this Multiple Sclerosis News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.
No more articles